Eisai Co., Ltd.: Lymphoma trials

The registry lists 21 Lymphoma studies with Eisai Co., Ltd. as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 1 9Phase 2 5Phase 3 2Phase 4 3No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101TerminatedNCT04144140Phase 1Results posted
• Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene MutationCompletedNCT03456726Phase 2Results posted
• A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT03009344Phase 1Results posted
• Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell LymphomaCompletedNCT02676778Phase 2Results posted
• A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.CompletedNCT02578316Phase 1Results posted
• This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including LymphomasCompletedNCT02171260Phase 1Results posted
• A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell LymphomaCompletedNCT01871727Phase 3Results posted
• E7777 for the Treatment of Patients With Peripheral T-Cell LymphomaCompletedNCT01401530Phase 1Results posted
• A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell LymphomaCompletedNCT00211185Phase 2Results posted
• An Open Label Dose Escalation Study Of E7080CompletedNCT00121719Phase 1Results posted
• Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)CompletedNCT00051025Phase 2Results posted
• A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)CompletedNCT05137847
• MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT01748721Phase 1
• A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc IntervalCompletedNCT01525394Phase 1
• A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell LymphomaWithdrawnNCT01355783Phase 3
• Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter PyloriCompletedNCT01264822
• A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's LymphomaCompletedNCT00211276Phase 2
• Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)CompletedNCT00211198Phase 4
• Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or LymphomaCompletedNCT00078637Phase 1
• Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma PatientsCompletedNCT00051012Phase 4
• Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) PatientsCompletedNCT00050999Phase 4